PMC:7212949 / 72150-73116 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T397","span":{"begin":207,"end":218},"obj":"Body_part"},{"id":"T398","span":{"begin":233,"end":238},"obj":"Body_part"},{"id":"T399","span":{"begin":410,"end":415},"obj":"Body_part"},{"id":"T400","span":{"begin":656,"end":667},"obj":"Body_part"},{"id":"T401","span":{"begin":693,"end":697},"obj":"Body_part"},{"id":"T402","span":{"begin":755,"end":763},"obj":"Body_part"},{"id":"T403","span":{"begin":796,"end":807},"obj":"Body_part"}],"attributes":[{"id":"A397","pred":"fma_id","subj":"T397","obj":"http://purl.org/sig/ont/fma/fma62863"},{"id":"A398","pred":"fma_id","subj":"T398","obj":"http://purl.org/sig/ont/fma/fma9670"},{"id":"A399","pred":"fma_id","subj":"T399","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A400","pred":"fma_id","subj":"T400","obj":"http://purl.org/sig/ont/fma/fma62863"},{"id":"A401","pred":"fma_id","subj":"T401","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A402","pred":"fma_id","subj":"T402","obj":"http://purl.org/sig/ont/fma/fma62851"},{"id":"A403","pred":"fma_id","subj":"T403","obj":"http://purl.org/sig/ont/fma/fma62863"}],"text":"Key findings on investigations • Moderate lymphopenia (69.6%), continued to drop\n• Thrombocytopenia on admission (44.8%)\n• ↑D-Dimer (45%)\n• Prolonged aPTT(42.8%)\n• Leukopenia on admission (33.9%)\n• Reactive lymphocytes in peripheral blood (15.2%) • Lymphopenia (98%)\n• Neutrophilia (82%)\n• Prolonged apTT (63%)\n• Hb↓ by \u003e20g/L (61%)\n• Thrombocytopenia (55%)\n• Thrombocytosis (49%),\n• DIC (2.5%)\n• ↓ CD4+, CD8+ cells • Moderate lymphopenia (61.5%, 80.6% at days 5,10)\n• Leukopenia (19.7%, 50%)\n• Severe lymphopenia (9.8, 18.9%)\n• Severe leukopenia (3.3%, after day 5)\n• Thrombocytopenia (2.5%, 6.6% at days 5, 10)\n• Severe neutropenia (1.6%, 5%)\n• Reactive lymphocytes absent\nV shaped trend of cell lines:• Hb nadir: Day 12\n• WBC (ANC) nadir: Day 7 or 8\n• Platelet nadir: Day 6 or 7\n• Prolonged ↓ lymphocytes in ICU group, no recovery by Day 12 • Lymphopenia (68-100%)\n• Thrombocytopenia (20-55%)\n• Leukopenia (19.4-64%)\n• Thrombocytosis in recovery with elevated TPO"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T191","span":{"begin":233,"end":238},"obj":"Body_part"}],"attributes":[{"id":"A191","pred":"uberon_id","subj":"T191","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"}],"text":"Key findings on investigations • Moderate lymphopenia (69.6%), continued to drop\n• Thrombocytopenia on admission (44.8%)\n• ↑D-Dimer (45%)\n• Prolonged aPTT(42.8%)\n• Leukopenia on admission (33.9%)\n• Reactive lymphocytes in peripheral blood (15.2%) • Lymphopenia (98%)\n• Neutrophilia (82%)\n• Prolonged apTT (63%)\n• Hb↓ by \u003e20g/L (61%)\n• Thrombocytopenia (55%)\n• Thrombocytosis (49%),\n• DIC (2.5%)\n• ↓ CD4+, CD8+ cells • Moderate lymphopenia (61.5%, 80.6% at days 5,10)\n• Leukopenia (19.7%, 50%)\n• Severe lymphopenia (9.8, 18.9%)\n• Severe leukopenia (3.3%, after day 5)\n• Thrombocytopenia (2.5%, 6.6% at days 5, 10)\n• Severe neutropenia (1.6%, 5%)\n• Reactive lymphocytes absent\nV shaped trend of cell lines:• Hb nadir: Day 12\n• WBC (ANC) nadir: Day 7 or 8\n• Platelet nadir: Day 6 or 7\n• Prolonged ↓ lymphocytes in ICU group, no recovery by Day 12 • Lymphopenia (68-100%)\n• Thrombocytopenia (20-55%)\n• Leukopenia (19.4-64%)\n• Thrombocytosis in recovery with elevated TPO"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T604","span":{"begin":42,"end":53},"obj":"Disease"},{"id":"T605","span":{"begin":83,"end":99},"obj":"Disease"},{"id":"T606","span":{"begin":164,"end":174},"obj":"Disease"},{"id":"T607","span":{"begin":249,"end":260},"obj":"Disease"},{"id":"T608","span":{"begin":335,"end":351},"obj":"Disease"},{"id":"T609","span":{"begin":360,"end":374},"obj":"Disease"},{"id":"T610","span":{"begin":427,"end":438},"obj":"Disease"},{"id":"T611","span":{"begin":469,"end":479},"obj":"Disease"},{"id":"T612","span":{"begin":502,"end":513},"obj":"Disease"},{"id":"T613","span":{"begin":536,"end":546},"obj":"Disease"},{"id":"T614","span":{"begin":569,"end":585},"obj":"Disease"},{"id":"T615","span":{"begin":622,"end":633},"obj":"Disease"},{"id":"T616","span":{"begin":846,"end":857},"obj":"Disease"},{"id":"T617","span":{"begin":870,"end":886},"obj":"Disease"},{"id":"T618","span":{"begin":898,"end":908},"obj":"Disease"},{"id":"T619","span":{"begin":922,"end":936},"obj":"Disease"}],"attributes":[{"id":"A604","pred":"mondo_id","subj":"T604","obj":"http://purl.obolibrary.org/obo/MONDO_0003783"},{"id":"A605","pred":"mondo_id","subj":"T605","obj":"http://purl.obolibrary.org/obo/MONDO_0002049"},{"id":"A606","pred":"mondo_id","subj":"T606","obj":"http://purl.obolibrary.org/obo/MONDO_0003785"},{"id":"A607","pred":"mondo_id","subj":"T607","obj":"http://purl.obolibrary.org/obo/MONDO_0003783"},{"id":"A608","pred":"mondo_id","subj":"T608","obj":"http://purl.obolibrary.org/obo/MONDO_0002049"},{"id":"A609","pred":"mondo_id","subj":"T609","obj":"http://purl.obolibrary.org/obo/MONDO_0002249"},{"id":"A610","pred":"mondo_id","subj":"T610","obj":"http://purl.obolibrary.org/obo/MONDO_0003783"},{"id":"A611","pred":"mondo_id","subj":"T611","obj":"http://purl.obolibrary.org/obo/MONDO_0003785"},{"id":"A612","pred":"mondo_id","subj":"T612","obj":"http://purl.obolibrary.org/obo/MONDO_0003783"},{"id":"A613","pred":"mondo_id","subj":"T613","obj":"http://purl.obolibrary.org/obo/MONDO_0003785"},{"id":"A614","pred":"mondo_id","subj":"T614","obj":"http://purl.obolibrary.org/obo/MONDO_0002049"},{"id":"A615","pred":"mondo_id","subj":"T615","obj":"http://purl.obolibrary.org/obo/MONDO_0001475"},{"id":"A616","pred":"mondo_id","subj":"T616","obj":"http://purl.obolibrary.org/obo/MONDO_0003783"},{"id":"A617","pred":"mondo_id","subj":"T617","obj":"http://purl.obolibrary.org/obo/MONDO_0002049"},{"id":"A618","pred":"mondo_id","subj":"T618","obj":"http://purl.obolibrary.org/obo/MONDO_0003785"},{"id":"A619","pred":"mondo_id","subj":"T619","obj":"http://purl.obolibrary.org/obo/MONDO_0002249"}],"text":"Key findings on investigations • Moderate lymphopenia (69.6%), continued to drop\n• Thrombocytopenia on admission (44.8%)\n• ↑D-Dimer (45%)\n• Prolonged aPTT(42.8%)\n• Leukopenia on admission (33.9%)\n• Reactive lymphocytes in peripheral blood (15.2%) • Lymphopenia (98%)\n• Neutrophilia (82%)\n• Prolonged apTT (63%)\n• Hb↓ by \u003e20g/L (61%)\n• Thrombocytopenia (55%)\n• Thrombocytosis (49%),\n• DIC (2.5%)\n• ↓ CD4+, CD8+ cells • Moderate lymphopenia (61.5%, 80.6% at days 5,10)\n• Leukopenia (19.7%, 50%)\n• Severe lymphopenia (9.8, 18.9%)\n• Severe leukopenia (3.3%, after day 5)\n• Thrombocytopenia (2.5%, 6.6% at days 5, 10)\n• Severe neutropenia (1.6%, 5%)\n• Reactive lymphocytes absent\nV shaped trend of cell lines:• Hb nadir: Day 12\n• WBC (ANC) nadir: Day 7 or 8\n• Platelet nadir: Day 6 or 7\n• Prolonged ↓ lymphocytes in ICU group, no recovery by Day 12 • Lymphopenia (68-100%)\n• Thrombocytopenia (20-55%)\n• Leukopenia (19.4-64%)\n• Thrombocytosis in recovery with elevated TPO"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T757","span":{"begin":133,"end":135},"obj":"http://purl.obolibrary.org/obo/CLO_0053799"},{"id":"T758","span":{"begin":233,"end":238},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"T759","span":{"begin":233,"end":238},"obj":"http://www.ebi.ac.uk/efo/EFO_0000296"},{"id":"T760","span":{"begin":313,"end":315},"obj":"http://purl.obolibrary.org/obo/CLO_0003622"},{"id":"T761","span":{"begin":399,"end":402},"obj":"http://purl.obolibrary.org/obo/PR_000001004"},{"id":"T762","span":{"begin":405,"end":408},"obj":"http://purl.obolibrary.org/obo/CLO_0053438"},{"id":"T763","span":{"begin":410,"end":415},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T764","span":{"begin":693,"end":703},"obj":"http://purl.obolibrary.org/obo/CLO_0000031"},{"id":"T765","span":{"begin":706,"end":708},"obj":"http://purl.obolibrary.org/obo/CLO_0003622"}],"text":"Key findings on investigations • Moderate lymphopenia (69.6%), continued to drop\n• Thrombocytopenia on admission (44.8%)\n• ↑D-Dimer (45%)\n• Prolonged aPTT(42.8%)\n• Leukopenia on admission (33.9%)\n• Reactive lymphocytes in peripheral blood (15.2%) • Lymphopenia (98%)\n• Neutrophilia (82%)\n• Prolonged apTT (63%)\n• Hb↓ by \u003e20g/L (61%)\n• Thrombocytopenia (55%)\n• Thrombocytosis (49%),\n• DIC (2.5%)\n• ↓ CD4+, CD8+ cells • Moderate lymphopenia (61.5%, 80.6% at days 5,10)\n• Leukopenia (19.7%, 50%)\n• Severe lymphopenia (9.8, 18.9%)\n• Severe leukopenia (3.3%, after day 5)\n• Thrombocytopenia (2.5%, 6.6% at days 5, 10)\n• Severe neutropenia (1.6%, 5%)\n• Reactive lymphocytes absent\nV shaped trend of cell lines:• Hb nadir: Day 12\n• WBC (ANC) nadir: Day 7 or 8\n• Platelet nadir: Day 6 or 7\n• Prolonged ↓ lymphocytes in ICU group, no recovery by Day 12 • Lymphopenia (68-100%)\n• Thrombocytopenia (20-55%)\n• Leukopenia (19.4-64%)\n• Thrombocytosis in recovery with elevated TPO"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T71","span":{"begin":384,"end":387},"obj":"Chemical"},{"id":"T29187","span":{"begin":815,"end":820},"obj":"Chemical"}],"attributes":[{"id":"A77128","pred":"chebi_id","subj":"T71","obj":"http://purl.obolibrary.org/obo/CHEBI_4305"},{"id":"A47637","pred":"chebi_id","subj":"T71","obj":"http://purl.obolibrary.org/obo/CHEBI_53092"},{"id":"A80828","pred":"chebi_id","subj":"T29187","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"}],"text":"Key findings on investigations • Moderate lymphopenia (69.6%), continued to drop\n• Thrombocytopenia on admission (44.8%)\n• ↑D-Dimer (45%)\n• Prolonged aPTT(42.8%)\n• Leukopenia on admission (33.9%)\n• Reactive lymphocytes in peripheral blood (15.2%) • Lymphopenia (98%)\n• Neutrophilia (82%)\n• Prolonged apTT (63%)\n• Hb↓ by \u003e20g/L (61%)\n• Thrombocytopenia (55%)\n• Thrombocytosis (49%),\n• DIC (2.5%)\n• ↓ CD4+, CD8+ cells • Moderate lymphopenia (61.5%, 80.6% at days 5,10)\n• Leukopenia (19.7%, 50%)\n• Severe lymphopenia (9.8, 18.9%)\n• Severe leukopenia (3.3%, after day 5)\n• Thrombocytopenia (2.5%, 6.6% at days 5, 10)\n• Severe neutropenia (1.6%, 5%)\n• Reactive lymphocytes absent\nV shaped trend of cell lines:• Hb nadir: Day 12\n• WBC (ANC) nadir: Day 7 or 8\n• Platelet nadir: Day 6 or 7\n• Prolonged ↓ lymphocytes in ICU group, no recovery by Day 12 • Lymphopenia (68-100%)\n• Thrombocytopenia (20-55%)\n• Leukopenia (19.4-64%)\n• Thrombocytosis in recovery with elevated TPO"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T446","span":{"begin":42,"end":53},"obj":"Phenotype"},{"id":"T447","span":{"begin":83,"end":99},"obj":"Phenotype"},{"id":"T448","span":{"begin":164,"end":174},"obj":"Phenotype"},{"id":"T449","span":{"begin":249,"end":260},"obj":"Phenotype"},{"id":"T450","span":{"begin":269,"end":281},"obj":"Phenotype"},{"id":"T451","span":{"begin":335,"end":351},"obj":"Phenotype"},{"id":"T452","span":{"begin":360,"end":374},"obj":"Phenotype"},{"id":"T453","span":{"begin":384,"end":387},"obj":"Phenotype"},{"id":"T454","span":{"begin":427,"end":438},"obj":"Phenotype"},{"id":"T455","span":{"begin":469,"end":479},"obj":"Phenotype"},{"id":"T456","span":{"begin":502,"end":513},"obj":"Phenotype"},{"id":"T457","span":{"begin":536,"end":546},"obj":"Phenotype"},{"id":"T458","span":{"begin":569,"end":585},"obj":"Phenotype"},{"id":"T459","span":{"begin":622,"end":633},"obj":"Phenotype"},{"id":"T460","span":{"begin":846,"end":857},"obj":"Phenotype"},{"id":"T461","span":{"begin":870,"end":886},"obj":"Phenotype"},{"id":"T462","span":{"begin":898,"end":908},"obj":"Phenotype"},{"id":"T463","span":{"begin":922,"end":936},"obj":"Phenotype"}],"attributes":[{"id":"A446","pred":"hp_id","subj":"T446","obj":"http://purl.obolibrary.org/obo/HP_0001888"},{"id":"A447","pred":"hp_id","subj":"T447","obj":"http://purl.obolibrary.org/obo/HP_0001873"},{"id":"A448","pred":"hp_id","subj":"T448","obj":"http://purl.obolibrary.org/obo/HP_0001882"},{"id":"A449","pred":"hp_id","subj":"T449","obj":"http://purl.obolibrary.org/obo/HP_0001888"},{"id":"A450","pred":"hp_id","subj":"T450","obj":"http://purl.obolibrary.org/obo/HP_0011897"},{"id":"A451","pred":"hp_id","subj":"T451","obj":"http://purl.obolibrary.org/obo/HP_0001873"},{"id":"A452","pred":"hp_id","subj":"T452","obj":"http://purl.obolibrary.org/obo/HP_0001894"},{"id":"A453","pred":"hp_id","subj":"T453","obj":"http://purl.obolibrary.org/obo/HP_0005521"},{"id":"A454","pred":"hp_id","subj":"T454","obj":"http://purl.obolibrary.org/obo/HP_0001888"},{"id":"A455","pred":"hp_id","subj":"T455","obj":"http://purl.obolibrary.org/obo/HP_0001882"},{"id":"A456","pred":"hp_id","subj":"T456","obj":"http://purl.obolibrary.org/obo/HP_0001888"},{"id":"A457","pred":"hp_id","subj":"T457","obj":"http://purl.obolibrary.org/obo/HP_0001882"},{"id":"A458","pred":"hp_id","subj":"T458","obj":"http://purl.obolibrary.org/obo/HP_0001873"},{"id":"A459","pred":"hp_id","subj":"T459","obj":"http://purl.obolibrary.org/obo/HP_0001875"},{"id":"A460","pred":"hp_id","subj":"T460","obj":"http://purl.obolibrary.org/obo/HP_0001888"},{"id":"A461","pred":"hp_id","subj":"T461","obj":"http://purl.obolibrary.org/obo/HP_0001873"},{"id":"A462","pred":"hp_id","subj":"T462","obj":"http://purl.obolibrary.org/obo/HP_0001882"},{"id":"A463","pred":"hp_id","subj":"T463","obj":"http://purl.obolibrary.org/obo/HP_0001894"}],"text":"Key findings on investigations • Moderate lymphopenia (69.6%), continued to drop\n• Thrombocytopenia on admission (44.8%)\n• ↑D-Dimer (45%)\n• Prolonged aPTT(42.8%)\n• Leukopenia on admission (33.9%)\n• Reactive lymphocytes in peripheral blood (15.2%) • Lymphopenia (98%)\n• Neutrophilia (82%)\n• Prolonged apTT (63%)\n• Hb↓ by \u003e20g/L (61%)\n• Thrombocytopenia (55%)\n• Thrombocytosis (49%),\n• DIC (2.5%)\n• ↓ CD4+, CD8+ cells • Moderate lymphopenia (61.5%, 80.6% at days 5,10)\n• Leukopenia (19.7%, 50%)\n• Severe lymphopenia (9.8, 18.9%)\n• Severe leukopenia (3.3%, after day 5)\n• Thrombocytopenia (2.5%, 6.6% at days 5, 10)\n• Severe neutropenia (1.6%, 5%)\n• Reactive lymphocytes absent\nV shaped trend of cell lines:• Hb nadir: Day 12\n• WBC (ANC) nadir: Day 7 or 8\n• Platelet nadir: Day 6 or 7\n• Prolonged ↓ lymphocytes in ICU group, no recovery by Day 12 • Lymphopenia (68-100%)\n• Thrombocytopenia (20-55%)\n• Leukopenia (19.4-64%)\n• Thrombocytosis in recovery with elevated TPO"}

{"project":"LitCovid-sentences","denotations":[{"id":"T700","span":{"begin":0,"end":80},"obj":"Sentence"},{"id":"T701","span":{"begin":81,"end":120},"obj":"Sentence"},{"id":"T702","span":{"begin":121,"end":137},"obj":"Sentence"},{"id":"T703","span":{"begin":138,"end":161},"obj":"Sentence"},{"id":"T704","span":{"begin":162,"end":195},"obj":"Sentence"},{"id":"T705","span":{"begin":196,"end":266},"obj":"Sentence"},{"id":"T706","span":{"begin":267,"end":287},"obj":"Sentence"},{"id":"T707","span":{"begin":288,"end":310},"obj":"Sentence"},{"id":"T708","span":{"begin":311,"end":332},"obj":"Sentence"},{"id":"T709","span":{"begin":333,"end":357},"obj":"Sentence"},{"id":"T710","span":{"begin":358,"end":381},"obj":"Sentence"},{"id":"T711","span":{"begin":382,"end":394},"obj":"Sentence"},{"id":"T712","span":{"begin":395,"end":466},"obj":"Sentence"},{"id":"T713","span":{"begin":467,"end":492},"obj":"Sentence"},{"id":"T714","span":{"begin":493,"end":526},"obj":"Sentence"},{"id":"T715","span":{"begin":527,"end":566},"obj":"Sentence"},{"id":"T716","span":{"begin":567,"end":612},"obj":"Sentence"},{"id":"T717","span":{"begin":613,"end":644},"obj":"Sentence"},{"id":"T718","span":{"begin":645,"end":674},"obj":"Sentence"},{"id":"T719","span":{"begin":675,"end":715},"obj":"Sentence"},{"id":"T720","span":{"begin":716,"end":722},"obj":"Sentence"},{"id":"T721","span":{"begin":723,"end":741},"obj":"Sentence"},{"id":"T722","span":{"begin":742,"end":752},"obj":"Sentence"},{"id":"T723","span":{"begin":753,"end":770},"obj":"Sentence"},{"id":"T724","span":{"begin":771,"end":781},"obj":"Sentence"},{"id":"T725","span":{"begin":782,"end":867},"obj":"Sentence"},{"id":"T726","span":{"begin":868,"end":895},"obj":"Sentence"},{"id":"T727","span":{"begin":896,"end":919},"obj":"Sentence"},{"id":"T728","span":{"begin":920,"end":966},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Key findings on investigations • Moderate lymphopenia (69.6%), continued to drop\n• Thrombocytopenia on admission (44.8%)\n• ↑D-Dimer (45%)\n• Prolonged aPTT(42.8%)\n• Leukopenia on admission (33.9%)\n• Reactive lymphocytes in peripheral blood (15.2%) • Lymphopenia (98%)\n• Neutrophilia (82%)\n• Prolonged apTT (63%)\n• Hb↓ by \u003e20g/L (61%)\n• Thrombocytopenia (55%)\n• Thrombocytosis (49%),\n• DIC (2.5%)\n• ↓ CD4+, CD8+ cells • Moderate lymphopenia (61.5%, 80.6% at days 5,10)\n• Leukopenia (19.7%, 50%)\n• Severe lymphopenia (9.8, 18.9%)\n• Severe leukopenia (3.3%, after day 5)\n• Thrombocytopenia (2.5%, 6.6% at days 5, 10)\n• Severe neutropenia (1.6%, 5%)\n• Reactive lymphocytes absent\nV shaped trend of cell lines:• Hb nadir: Day 12\n• WBC (ANC) nadir: Day 7 or 8\n• Platelet nadir: Day 6 or 7\n• Prolonged ↓ lymphocytes in ICU group, no recovery by Day 12 • Lymphopenia (68-100%)\n• Thrombocytopenia (20-55%)\n• Leukopenia (19.4-64%)\n• Thrombocytosis in recovery with elevated TPO"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T1574","span":{"begin":19,"end":30},"obj":"CL:0000542"},{"id":"T1575","span":{"begin":146,"end":160},"obj":"GO:0007596"},{"id":"T1576","span":{"begin":200,"end":205},"obj":"NCBITaxon:10239"},{"id":"T1577","span":{"begin":216,"end":229},"obj":"GO:0030097;CL:0000037"},{"id":"T1578","span":{"begin":230,"end":240},"obj":"CL:0000037"},{"id":"T1579","span":{"begin":245,"end":259},"obj":"CL:0000556"},{"id":"T1580","span":{"begin":294,"end":298},"obj":"UBERON:0002048"},{"id":"T1581","span":{"begin":353,"end":366},"obj":"GO:0019835"},{"id":"T1582","span":{"begin":560,"end":572},"obj":"GO:0030097"},{"id":"T1583","span":{"begin":638,"end":652},"obj":"GO:0007596"},{"id":"T1584","span":{"begin":926,"end":938},"obj":"GO:0030097"},{"id":"T1585","span":{"begin":940,"end":950},"obj":"CL:0000775"}],"text":"Key findings on investigations • Moderate lymphopenia (69.6%), continued to drop\n• Thrombocytopenia on admission (44.8%)\n• ↑D-Dimer (45%)\n• Prolonged aPTT(42.8%)\n• Leukopenia on admission (33.9%)\n• Reactive lymphocytes in peripheral blood (15.2%) • Lymphopenia (98%)\n• Neutrophilia (82%)\n• Prolonged apTT (63%)\n• Hb↓ by \u003e20g/L (61%)\n• Thrombocytopenia (55%)\n• Thrombocytosis (49%),\n• DIC (2.5%)\n• ↓ CD4+, CD8+ cells • Moderate lymphopenia (61.5%, 80.6% at days 5,10)\n• Leukopenia (19.7%, 50%)\n• Severe lymphopenia (9.8, 18.9%)\n• Severe leukopenia (3.3%, after day 5)\n• Thrombocytopenia (2.5%, 6.6% at days 5, 10)\n• Severe neutropenia (1.6%, 5%)\n• Reactive lymphocytes absent\nV shaped trend of cell lines:• Hb nadir: Day 12\n• WBC (ANC) nadir: Day 7 or 8\n• Platelet nadir: Day 6 or 7\n• Prolonged ↓ lymphocytes in ICU group, no recovery by Day 12 • Lymphopenia (68-100%)\n• Thrombocytopenia (20-55%)\n• Leukopenia (19.4-64%)\n• Thrombocytosis in recovery with elevated TPO"}